Inclusion Criteria:

          1. Confirmed diagnosis of Isocitrate Dehydrogenase 1 (IDH1) wild-type glioblastoma on
             pathology from initial surgery (e.g. IDH R132H neg)

          2. Ability to undergo contrast-enhanced MRI

          3. Radiographic evidence of tumor recurrence/progression after failure of 1 - 2 lines of
             prior therapy

          4. Measurable or evaluable disease

               1. Measurable: contrast-enhancement (bidirectional diameters ≥ 1cm) on MRI

               2. Non-measurable/evaluable: contrast-enhancement diameters < 1 cm

          5. Maximal tumor diameter pre-surgery ≤ 70 mm on T1wMRI

          6. Candidate for at least partial surgical resection

          7. Greater 12 weeks from completion of radiation therapy

          8. Age ≥ 18 years

          9. Stable or decreasing dose of corticosteroids equivalent to ≤ 6 mg dexamethasone, for ≥
             7 days prior to registration

         10. WHO performance status ≤ 2 (equivalent to Karnofsky Performance Status (KPS) of ≥70)

         11. Adequate hepatic, renal and bone marrow function, documented with normal laboratory
             values or no more than grade 1 outside the norm performed within 14 days prior to
             registration

         12. For patients with a childbearing potential

               1. Negative pregnancy test within 14 days prior to registration

               2. Agreement to use adequate contraception for the duration of study participation,
                  and for 3 and 6 months after the last dose of nab-paclitaxel for men and women of
                  childbearing potential, respectively.

         13. Have the ability to understand and the willingness to sign a written informed consent
             prior to registration on study

         14. Be willing and able to comply with the protocol for the duration of the study

         15. Provide written, signed and dated informed consent prior to study registration. NOTE:
             no study-specific screening procedures may be performed until written consent has been
             obtained

        Exclusion Criteria:

          1. Have multifocal disease that cannot be encompassed in the ultrasound fields:

               1. e.g. > 70-mm apart

               2. tumor located in the posterior fossa

          2. Patients at risk of cranial wound dehiscence

          3. Have uncontrolled epilepsy or require treatment with enzyme-inducing antiepileptics

          4. Have clinical evidence of peripheral neuropathy on examination

          5. Have received any other investigational agents within 4 weeks of registration

          6. Have received prior therapy with or have history of allergic reactions attributed to
             compounds of similar chemical or biologic composition to paclitaxel

          7. Medical contraindications to Abraxane®

          8. Have an uncontrolled intercurrent illness

          9. Are pregnant or nursing

         10. Have a history of active malignancy within 3 years prior to registration.

         11. Have a known history of hypersensitivity reactions to perflutren lipid microsphere
             components or to any of the inactive ingredients in Definity® (the FDA-approved
             ultrasound contrast agent to be used in this study)

         12. Patients with coils, clips, shunts, intravascular stents, and/or non-removable wafer,
             non resorbable dura substitute, or reservoirs.

         13. Patients with medical need to continue antiplatelet therapy.